Melphalan Koanaa (Melphalan)

Melphalan works by alkylating the N7 position of guanine bases in DNA, creating cross‑links that prevent DNA replication and transcription. This damage triggers cell‑cycle arrest and apoptosis, especially in fast‑growing tumour cells.

The specific dose of melphalan is individualized by the prescribing oncologist based on the patient’s diagnosis, disease stage, body surface area and renal function. Only a qualified healthcare professional should determine the appropriate dosing schedule.

Melphalan is classified as potentially harmful to the fetus and is generally contraindicated during pregnancy unless the therapeutic benefit outweighs the risk. It is also excreted in breast milk, so breastfeeding is not recommended while receiving treatment.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Melphalan shares the DNA‑cross‑linking mechanism common to nitrogen‑mustard alkylators but differs in its pharmacokinetic profile and spectrum of activity. Compared with agents such as cyclophosphamide, melphalan is often preferred for certain haematologic malignancies and high‑dose regimens because of its potency and tissue penetration.

Melphalan Koanaa must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. The product should be kept in its original packaging until use, and preparation should follow aseptic technique in a controlled environment.

The drug is supplied as an injectable solution for intra‑arterial or intravenous infusion. Administration is performed by qualified healthcare personnel in a clinical setting, following the prescribed infusion rate and monitoring guidelines to manage potential reactions.

Serious risks include severe bone‑marrow suppression leading to infection or bleeding, secondary malignancies such as acute leukemia, pulmonary toxicity, renal failure, and cardiac complications. Patients should be monitored closely for signs of infection, respiratory distress, renal dysfunction and abnormal cardiac rhythms.

Melphalan is contraindicated in patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, in those with severe uncontrolled infections, and in pregnant or lactating women unless absolutely necessary. Caution is also advised for individuals with significant renal impairment or pre‑existing bone‑marrow failure.